Guanfacine Clinical Trial for Smoking Cessation

Summary

Adult daily smokers motivated to quit smoking will be randomized to extended-release guanfacine (6mg/day) or placebo and will enroll in an 8-week treatment period combining medication with brief behavioral support. The investigators hypothesize that the active dose of guanfacine compared to placebo will increase rates of prolonged smoking abstinence at the end of the 8-week treatment phase.

Timeline

Start

2014-03

Primary completion

2020-11

Completion

2020-11

Drugs

Indications

No indication recorded.